Literature DB >> 27156895

Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Jason P Holland1, Riccardo Ferdani2, Carolyn J Anderson2, Jason S Lewis1.   

Abstract

The positron emitting radionuclide (64)Cu has a radioactive half-life of 12.7 hours. The decay characteristics of (64)Cu allow for PET images that are comparable in quality to those obtained using (18)F. Given the longer radioactive half-life of (64)Cu compared with (18)F and the versatility of copper chemistry, copper is an attractive alternative to the shorter-lived nuclides for PET imaging of peptides, antibodies, and small molecules that may require longer circulation times. This article discusses a number of copper radiopharmaceuticals, such as Cu-ATSM, that have been translated to the clinic and new developments in copper-based radiopharmaceuticals.

Entities:  

Year:  2009        PMID: 27156895      PMCID: PMC4961094          DOI: 10.1016/j.cpet.2009.04.013

Source DB:  PubMed          Journal:  PET Clin        ISSN: 1556-8598


  166 in total

Review 1.  Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly.

Authors:  John S Bevan
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Workshop on the production, application and clinical translation of ''non-standard'' PET nuclides: a meeting report.

Authors:  J S Lewis; M J Welch; L Tang
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

Review 3.  Magnetic nanoparticles in MR imaging and drug delivery.

Authors:  Conroy Sun; Jerry S H Lee; Miqin Zhang
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

4.  Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.

Authors:  P M van Hagen; W A Breeman; H F Bernard; M Schaar; C M Mooij; A Srinivasan; M A Schmidt; E P Krenning; M de Jong
Journal:  Int J Cancer       Date:  2000-08-20       Impact factor: 7.396

Review 5.  Integrins as dynamic regulators of vascular function.

Authors:  F W Luscinskas; J Lawler
Journal:  FASEB J       Date:  1994-09       Impact factor: 5.191

6.  Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.

Authors:  Richard Laforest; Farrokh Dehdashti; Jason S Lewis; Sally W Schwarz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-23       Impact factor: 9.236

7.  Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores.

Authors:  Hisataka Kobayashi; Satomi Kawamoto; Sang-Kyung Jo; Henry L Bryant; Martin W Brechbiel; Robert A Star
Journal:  Bioconjug Chem       Date:  2003 Mar-Apr       Impact factor: 4.774

8.  (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.

Authors:  Zi-Bo Li; Weibo Cai; Qizhen Cao; Kai Chen; Zhanhong Wu; Lina He; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2007-06-15       Impact factor: 10.057

9.  Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting.

Authors:  Marcel Janssen; Wim J G Oyen; Leon F A G Massuger; Cathelijne Frielink; Ingrid Dijkgraaf; D Scott Edwards; Milind Radjopadhye; Frans H M Corstens; Otto C Boerman
Journal:  Cancer Biother Radiopharm       Date:  2002-12       Impact factor: 3.099

Review 10.  Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours.

Authors:  W W de Herder; L J Hofland; A J van der Lely; S W J Lamberts
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

View more
  2 in total

Review 1.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

2.  Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis.

Authors:  Daniel F Earley; Jose Esteban Flores; Amaury Guillou; Jason P Holland
Journal:  Dalton Trans       Date:  2022-03-29       Impact factor: 4.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.